181 related articles for article (PubMed ID: 35790845)
1. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
[TBL] [Abstract][Full Text] [Related]
2. The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion.
Dembitz V; Tomic B; Kodvanj I; Simon JA; Bedalov A; Visnjic D
J Biol Chem; 2019 Oct; 294(42):15257-15270. PubMed ID: 31431503
[TBL] [Abstract][Full Text] [Related]
3. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
[TBL] [Abstract][Full Text] [Related]
4. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
[TBL] [Abstract][Full Text] [Related]
6.
Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
9. CHK1 as a therapeutic target to bypass chemoresistance in AML.
David L; Fernandez-Vidal A; Bertoli S; Grgurevic S; Lepage B; Deshaies D; Prade N; Cartel M; Larrue C; Sarry JE; Delabesse E; Cazaux C; Didier C; Récher C; Manenti S; Hoffmann JS
Sci Signal; 2016 Sep; 9(445):ra90. PubMed ID: 27625304
[TBL] [Abstract][Full Text] [Related]
10. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
12. Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
Hubackova S; Davidova E; Boukalova S; Kovarova J; Bajzikova M; Coelho A; Terp MG; Ditzel HJ; Rohlena J; Neuzil J
Cell Death Dis; 2020 Feb; 11(2):110. PubMed ID: 32034120
[TBL] [Abstract][Full Text] [Related]
13. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Zhou J; Yiying Quah J; Ng Y; Chooi JY; Hui-Min Toh S; Lin B; Zea Tan T; Hosoi H; Osato M; Seet Q; Ooi LAG; Lindmark B; McHale M; Chng WJ
Haematologica; 2020 Sep; 105(9):2286-2297. PubMed ID: 33054053
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia.
Zhang Y; Luo T; Ding X; Chang Y; Liu C; Zhang Y; Hao S; Yin Q; Jiang B
Biochem Biophys Res Commun; 2021 Apr; 547():162-168. PubMed ID: 33610916
[TBL] [Abstract][Full Text] [Related]
15. The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Gaidano V; Houshmand M; Vitale N; Carrà G; Morotti A; Tenace V; Rapelli S; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Cilloni D; Cignetti A; Saglio G; Circosta P
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670894
[TBL] [Abstract][Full Text] [Related]
16. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
Vincelette ND; Ding H; Huehls AM; Flatten KS; Kelly RL; Kohorst MA; Webster J; Hess AD; Pratz KW; Karnitz LM; Kaufmann SH
Sci Rep; 2019 Mar; 9(1):3617. PubMed ID: 30837643
[TBL] [Abstract][Full Text] [Related]
17. Identification of second generation benzylidene chromanone analogues as novel, potent DHODH inhibitors in acute myeloid leukemia cells.
Abohassan M; Al Shahrani M; Rajagopalan P
J Biomol Struct Dyn; 2023; 41(13):6168-6177. PubMed ID: 35869648
[TBL] [Abstract][Full Text] [Related]
18. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
[TBL] [Abstract][Full Text] [Related]
19. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Branstrom A; Cao L; Furia B; Trotta C; Santaguida M; Graci JD; Colacino JM; Ray B; Li W; Sheedy J; Mollin A; Yeh S; Kong R; Sheridan R; Baird JD; O'Keefe K; Spiegel R; Goodwin E; Keating S; Weetall M
Front Oncol; 2022; 12():832816. PubMed ID: 35223511
[TBL] [Abstract][Full Text] [Related]
20. Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia.
Gaur T; Ali A; Sharma D; Gupta SK; Gota V; Bagal B; Platzbeckar U; Mishra R; Dutt A; Khattry N; Mills K; Hassan MI; Sandur S; Hasan SK
Cell Signal; 2024 Feb; 114():111004. PubMed ID: 38048856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
